The cellular neurobiology of depression
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Major depressive disorders, long considered to be of neurochemical origin, have recently been associated with impairments in signaling pathways that regulate neuroplasticity and cell survival. Agents designed to directly target molecules in these pathways may hold promise as new therapeutics for depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antidepressant therapies may compensate for this dysfunction by modulating the pathological limbic activity that putatively mediates depressive symptoms (Drevets et al, 2002a), or by enhancing the expression of neurotrophic factors that protect medial network function from the effects of repeated stress (Manji et al, 2001).”
From Neurocircuitry of Mood Disorders (2010) · cites this paper as Manji et al, 2001
In the citing paper
“Somatic antidepressant therapies may compensate for this dysfunction by modulating the pathological limbic activity which putatively mediates depressive symptoms (Drevets et al. 2002a) and the expression of neurotrophic/neuroprotective factors that preserve the function of the MPFC (Manji et al. 2001).”
From Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression (2008) · cites this paper as Manji et al. 2001
In the citing paper
“Depression is often associated with elevated HPA axis activity and increased levels of glucocorticoids, as well as disruption of negative feedback mechanisms21–23.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [22]
Citations
Cites
Neurogenesis in the adult human hippocampus
Eriksson, P. S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.-M., Nordborg, C., Peterson, D. A., & Gage, F. H. (1998) · Nature Medicine · doi:10.1038/3305 · Cited by 6,369 · cited 1×
“However, the demonstration that neurogenesis occurs in the adult human brain into senescenc”
BackgroundThe Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332 · cited 1×
“Modest changes in this signaling cascade or in the levels of the Bcl-2 family of proteins (potentially due to genetic, illness or insult-related factors) could therefore profoundly affect cellular viabilit”
BackgroundGlobal mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“It is thus not altogether surprising that the Global Burden of Disease Study has identified MDDs among the leading causes of disability worldwide, and as illnesses likely to represent an increasingly greater health, societal and economic problem in the coming year”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“Current research is examining the potential efficacy of antagonists of corticotropin-releasing factor (CRF), antiglucocorticoids and direct and indirect glutamate antagonist”
BackgroundSelf-citationChronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111 · cited 1×
“These studies demonstrate that chronic administration of different classes of antidepressants increases the proliferation and survival of new neuron”
BackgroundPsychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301 · cited 1×
“Moreover, lithium also inhibits the activity of glycogen synthase kinase 3β (GSK-3β”
BackgroundThe Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129 · cited 1×
“have demonstrated that an important pathway involved in cell survival and plasticity, the cAMP–CREB cascade, is up-regulated by antidepressant treatmen”
BackgroundTHE EFFECTS OF STRESSFUL LIFE EVENTS ON DEPRESSION
Kessler, R. C. (1997) · Annual Review of Psychology · doi:10.1146/annurev.psych.48.1.191 · Cited by 2,111 · cited 1×
“Thus, although MDDs undoubtedly have a strong genetic basis, severe stressors have been associated with a substantial increase in risk for the onset of MDDs in susceptible individuals ( Table 3”
Background
Research works printed but not linked: 4
- Garlow, S.J., Musselman, D.L. & Nemeroff C.B. The Neurochemistry of Mood Disorders clinical studies. in Neurobiology of Mental Illness. (eds. Charney, D.S., Nester, E.J. & Bunney, B.S.) 348–364 (Oxford Press, New York, 1999).
- Drevets, W.C., Gadde, K. & Krishnan, R. Neuroimaging studies of depression. in Neurobiology of Mental Illness. (eds. Charney, D.S., Nester, E.J. & Bunney, B.S.) 394–418 (Oxford Press, New York, 1999).
- LeDoux, J.E. Emotion. in Handbook of Physiology—The Nervous System, Vol. V. (eds. Mills, J., Mountcastle, V.B., Plum, F. & Geiger, S.R.) 373–417 (Williams & Wilkins, Baltimore, 1987).
- Manji, H.K. et al. Regulation of signal transduction pathways by mood stabilizing agents: Implications for the pathophysiology and treatment of bipolar affective disorder. in Bipolar Medications: Mechanisms of Action. (eds. Manji, H.K., Bowden, C.L. & Belmaker, R.H.) 129–177 (American Psychiatric Press, Washington, DC, 2000).
Cited by
Items 301–400 of 1,000
Huang, X., Wu, D.-Y., Chen, G., Manji, H., & Chen, D. F. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0198 · Cited by 98
Self-citationMutlu, O., Gumuslu, E., Ulak, G., Celikyurt, I. K., Kokturk, S., Kır, H. M., Akar, F., & Erden, F. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.09.023 · Cited by 97
Chronic fluoxetine treatment increases the expression of PSA-NCAM in the medial prefrontal cortex
Varea, E., Blasco-Ibáñez, J. M., Gómez-Climent, M. Á., Castillo-Gómez, E., Crespo, C., Martínez-Guijarro, F. J., & Nácher, J. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301183 · Cited by 96
“In fact, antidepressant drugs may act by normalizing this impairment (Duman et al, 1999; Manji et al, 2000, 2001; Manji and Duman, 2001).”
BackgroundVouimba, R.-M., Muñoz, C., & Diamond, D. M. (2006) · Stress · doi:10.1080/10253890600610973 · Cited by 96
“There are also commonalities between the hippocampus and amygdala, such as their susceptibility to exhibit abnormalities in morphology and metabolism in people with PTSD and depression (Sheline et al. 1998; Manji et al. 2001; Drevets 2003; Kanner 2004; Perico et al. 2005).”
BackgroundSorCS2 is required for BDNF-dependent plasticity in the hippocampus
Glerup, S., Bølcho, U., Mølgaard, S., Boggild, S., Vægter, C. B., Smith, A. H., Nieto-González, J. L., Ovesen, P. L., Pedersen, L. F., Fjorback, A. N., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.108 · Cited by 105
Hisaoka, K., Takebayashi, M., Okada‐Tsuchioka, M., Maeda, N., Nakata, Y., & Yamawaki, S. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.116558 · Cited by 105
“Furthermore, a number of imaging and post-mortem studies in patients with mood disorders have revealed a reduction of particular areas such as the prefrontal cortex, hippocampus, and amygdala in total volume and cell density/size, especially glial cells (Öngür et al., 1998; Manji et al., 2001; Rajkowska, 2002).”
BackgroundGuiard, B., Mansari, M., & Blier, P. (2009) · Current Drug Targets · doi:10.2174/138945009789735156 · Cited by 90
“In particular, given that depression not only results from brain monoamines imbalance but involves other mechanisms such as cellular loss, atrophy, and abnormal neuronal connectivity in many brain areas [29], this review will address the possibility that triple reuptake inhibitors may exert more robust antidepressant…”
BackgroundHattori, S., Hashimoto, R., Miyakawa, T., Yamanaka, H., Maeno, H., Wada, K., & Kunugi, H. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.02.036 · Cited by 104
A central role for the acid sphingomyelinase/ceramide system in neurogenesis and major depression
Gulbins, E., Walter, S., Becker, K. A., Halmer, R., Liu, Y., Reichel, M., Edwards, M. J., Müller, C. P., Fassbender, K., & Kornhuber, J. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13145 · Cited by 93
Zhang, H., Etherington, L.-A., Hafner, A.-S., Belelli, D., Coussen, F., Delagrange, P., Chaouloff, F., Spedding, M., Lambert, J. J., Choquet, D., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.80 · Cited by 94
Mapping brain size and cortical gray matter changes in elderly depression
Ballmaier, M., Sowell, E. R., Thompson, P. M., Kumar, A., Narr, K. L., Lavretsky, H., Welcome, S. E., DeLuca, H., & Toga, A. W. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.004 · Cited by 91
An update on the role of glutamate in the pathophysiology of depression
Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01529.x · Cited by 91
Acute d-serine treatment produces antidepressant-like effects in rodents
Malkesman, O., Austin, D. R., Tragon, T., Wang, G., Rompala, G., Hamidi, A. B., Cui, Z., Young, W. S., Nakazawa, K., Zarate, C. A., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001386 · Cited by 92
“It is also important to note that for those patients who do respond to currently available antidepressants, clinical benefits often take weeks to occur, suggesting that many of the therapeutic effects are produced by changes in downstream signalling cascades (Krishnan & Nestler, 2008; Manji et al. 2001).”
BackgroundSelf-citationA longitudinal study of BDNF promoter methylation and genotype with poststroke depression
Kim, J., Stewart, R. J., Kang, H., Kim, S., Kim, S., Shin, I., Park, M., Kim, H., Shin, M., Cho, K.-H., et al. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.008 · Cited by 99
“Second, BDNF appears to have survival-promoting actions on a variety of CNS structures including hippocampal, cortical, cholinergic, dopaminergic and serotonergic neurons (Manji et al., 2001).”
BackgroundNeural plasticity: consequences of stress and actions of antidepressant treatment
Duman, R. S. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.2/rduman · Cited by 92
Casarotto, S., Canali, P., Rosanova, M., Pigorini, A., Fecchio, M., Mariotti, M., Lucca, A., Colombo, C., Benedetti, F., & Massimini, M. (2013) · Brain Topography · doi:10.1007/s10548-012-0256-8 · Cited by 89
“…ECT, fit with the observation that while stress reduces the expression of BDNF in the hippocampus and frontal cortex, antidepressants produce the opposite effect and promote neurons/glia survival and growth (Manji et al. 2001; Dwivedi et al. 2003; Salvadore et al. 2011; Duman and Voleti 2012).”
BackgroundResultInfluentialHetzel, G., Moeller, O., Evers, S., Erfurth, A., Ponath, G. D., Arolt, V., & Rothermundt, M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1999-z · Cited by 93
“This volume loss was due to a reduction of neuropil and synapses while the number of neurons was unchanged (Manji et al. 2001).”
BackgroundPérez‐Ruixo, C., Rossenu, S., Zannikos, P., Nandy, P., Singh, J. B., Drevets, W. C., & Ruixo, J. J. P. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00953-4 · Cited by 97
Self-citationReview on EEG and ERP predictive biomarkers for major depressive disorder
Mumtaz, W., Malik, A. S., Yasin, M. A. M., & Xia, L. (2015) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2015.07.003 · Cited by 99
Inhibition of G protein‐activated inwardly rectifying K+ channels by fluoxetine (Prozac)
Kobayashi, T., Washiyama, K., & Ikeda, K. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705172 · Cited by 89
“Recent studies have demonstrated that there are regional abnormalities in the prefrontal cortex, hippocampus, amygdala, thalamus and ventral striatum in depressed individuals (Manji et al., 2001).”
BackgroundGalanin as a modulator of anxiety and depression and a therapeutic target for affective disease
Karlsson, R., & Holmes, A. (2006) · Amino Acids · doi:10.1007/s00726-006-0336-8 · Cited by 100
“The temporal lag between the start of antidepressant treatment and the onset of clinical benefits is believed to reflect the need for downstream neural adaptations that are as yet unclear (Duman, 1998; Manji et al., 2001 ).”
BackgroundKetamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87
Differential urinary metabolites related with the severity of major depressive disorder
Chen, J., Zhou, C., Zheng, P., Cheng, K., Wang, H., Li, J., Zeng, L., & Xie, P. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.06.012 · Cited by 92
“A review reported that the signaling pathways, which were involved in regulating cell death and survival, were usually the long-term targets for antidepressants [35].”
BackgroundJiang, B., Wang, H., Wang, J., Wang, Y., Zhu, Q., Wang, C., Song, L., Gao, T., Wang, Y., Meng, G., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.10.004 · Cited by 93
Quan, M., Zhang, N., Wang, Y.-Y., Zhang, T., & Yang, Z. R. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.03.026 · Cited by 89
Neural correlates of treatment outcome in major depression
Lisiecka, D., Meisenzahl, E., Scheuerecker, J., Schoepf, V., Whitty, P., Chaney, A., Moeller, H.-J., Wiesmann, M., & Frodl, T. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001513 · Cited by 85
“The aetiology of the disease is circuit based (Anand et al. 2007; Manji et al. 2001 ; Mayberg, 2003 ; Nestler et al. 2002b) and involves changes in various parts of the brain including the ventrolateral prefrontal cortex (Seminowicz et al. 2004), dorsolateral prefrontal cortex (DLPFC) (Grimm et al.…”
BackgroundWang, Z., Gu, J., Wang, X., Xie, K., Luan, Q., Wan, N., Zhang, Q., Jiang, H., & Liu, D. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.007 · Cited by 93
“Recent research indicates that signal pathway related to synaptic plasticity may be the mechanism of antidepressant action and the pathophysiology of depression (Manji et al., 2001).”
Hippocampal volume and cell number in depression, schizophrenia, and suicide subjects
Chen, F., Bertelsen, A., Holm, I. E., Nyengaard, J. R., Rosenberg, R., & Dorph‐Petersen, K. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146546 · Cited by 93
A role for the extracellular signal-regulated kinase signal pathway in depressive-like behavior
Qi, X., Lin, W., Wang, D., Pan, Y., Wang, W., & Sun, M. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.11.051 · Cited by 98
Sun, H.-L., Zhou, Z.-Q., Zhang, G.-F., Yang, C., Wang, X.-M., Shen, J.-C., Hashimoto, K., & Yang, J.-J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.21 · Cited by 84
Carrier, N., & Kabbaj, M. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.028 · Cited by 84
Future antidepressant targets: neurotrophic factors and related signaling cascades
Schmidt, H. D., Banasr, M., & Duman, R. S. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.10.003 · Cited by 93
“The structural changes observed in the hippocampus, amygdala and prefrontal cortex of depressed patients may be due to many factors, including death or atrophy of existing neurons, decreases in the size and number of glia, and decreases in neurogenesis [7-9].”
BackgroundAntidepressant drug treatment induces Arc gene expression in the rat brain
Pei, Q., Zetterström, T., Sprakes, M., Tordera, R. M., & Sharp, T. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00504-9 · Cited by 82
Surtees, P. G., Wainwright, N. W. J., Willis‐Owen, S. A. G., Sandhu, M. S., Luben, R., Day, N., & Flint, J. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.01.004 · Cited by 91
Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex
Nocjar, C., Alex, K. D., Sonneborn, A., Abbas, A. I., Roth, B. L., & Pehek, E. A. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.03.050 · Cited by 85
“…subtypes (Hoyer et al., 1994;Roth et al., 2000;Berger et al., 2009), is thought to play an important role in these psychological disorders (Roth and Meltzer, 1995;Kosten et al., 1998;Aghajanian and Marek, 2000;Manji et al., 2001;Nestler et al., 2002;Celada et al., 2004;Cunningham et al., 2013).”
BackgroundWagner, G., Koch, K., Schachtzabel, C., Sobanski, T., Reichenbach, J. R., Sauer, H., & Schlösser, R. G. M. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.090081 · Cited by 81
“Therefore, an ongoing effect of antidepressants even after discontinuation could not be entirely ruled out, particularly in light of the long-term downstream adaptive processes on pre- and postsynaptic receptors and of changes in the intracellular signaling pathways.(39) To exclude any potential long-term effects of a…”
Réus, G. Z., Abelaira, H. M., Stringari, R. B., Fries, G. R., Kapczinski, F., & Quevedo, J. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9281-2 · Cited by 81
“Depression is a mood disorder, which affects up to 20% of the world population (Nestler et al. 2002; Manji et al. 2001).”
BackgroundKamitani, W., Ono, E., Yoshino, S., Kobayashi, T., Taharaguchi, S., Lee, B.-J., Yamashita, M., Kobayashi, T., Okamoto, M., Taniyama, H., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1531155100 · Cited by 79
Reduced neurogenesis and pre-synaptic dysfunction in the olfactory bulb of a rat model of depression
Yang, D., Li, Q., Fang, L., Cheng, K., Zhang, R., Zheng, P., Zhan, Q., Qi, Z., Zhong, S., & Xie, P. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.043 · Cited by 84
“Irrespective of stress and depression affecting hippocampal neurogenesis, the heterogeneity of depression implies that manifold neural substrates and mechanisms contribute to its etiology (Manji et al., 2001; Duman, 2002; Nestler et al., 2002).”
Dow, A. L., Russell, D. S., & Duman, R. S. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5155-04.2005 · Cited by 78
“Stress, emotional trauma, and environmental and genetic factors have all been implicated in precipitating depression (Duman et al., 2000, 2001; Manji et al., 2001; Nestler et al., 2002), but the underlying causes of depression are still unknown.”
BackgroundBreuer, M. E., Groenink, L., Oosting, R. S., Buerger, E., Korte, S. M., Ferger, B., & Olivier, B. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.029 · Cited by 78
Indole Acetic Acid Exerts Anti-Depressive Effects on an Animal Model of Chronic Mild Stress
Chen, Y., Tian, P., Wang, Z., Pan, R., Shang, K., Wang, G., Zhao, J., & Chen, W. (2022) · Nutrients · doi:10.3390/nu14235019 · Cited by 85
“Recent studies have implicated abnormalities in multiple systems in depressed individuals, namely, the serotonergic, noradrenergic, dopaminergic, cholinergic, glutamatergic and GABAergic systems; the corticotropic-releasing factor (CRF) and hypothalamus–pituitary–adrenal (HPA) axis; and neurophysiology [3].”
BackgroundConnecting Dots between Mitochondrial Dysfunction and Depression
Khan, M., Baussan, Y., & Hébert-Chatelain, É. (2023) · Biomolecules · doi:10.3390/biom13040695 · Cited by 82
“These brain regions are involved in affective and cognitive impairments observed in depression [77].”
BackgroundGelenberg, A. J., Thase, M. E., Meyer, R. E., Goodwin, F. K., Katz, M. M., Kraemer, H. C., Potter, W. Z., Shelton, R. C., Fava, M., Khan, A., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1001 · Cited by 79
Self-citationInflammation and depression: Is there a causal connection with dementia?
E.Leonard, B., & Myint, A. (2006) · Neurotoxicity Research · doi:10.1007/bf03033243 · Cited by 76
“This supports the hypothesis that depression is associated with compromised information processing involving critical neuronal networks (Manji et al., 2001).”
BackgroundBenzodiazepine use in Belgian nursing homes: a closer look into indications and dosages
Bourgeois, J., Elseviers, M. M., Azermai, M., Bortel, L. M. V., Petrović, M., & Stichele, R. V. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1188-z · Cited by 81
“At the onset of treatment of depression, a benzodiazepine could be used as an adjuvant, as the anti-anxiety effect of some antidepressants can take 2 to 4 weeks [42].”
Contributions of animal models to the study of mood disorders
Valvassori, S. S., Budni, J., Varela, R. B., & Quevedo, J. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1168 · Cited by 81
Heckman, P. R. A., Blokland, A., Bollen, E. P. P., & Prickaerts, J. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.007 · Cited by 74
Oxidative Imbalance and Anxiety Disorders
Krolow, R., Arcego, D. M., Noschang, C. G., Weis, S. N., & Dalmaz, C. (2014) · Current Neuropharmacology · doi:10.2174/1570159x11666131120223530 · Cited by 79
“During stressful conditions, overstimulation of glutamatergic transmission causes a sustained intracellular calcium influx leading to excessive mitochondrial calcium sequestration [51], mitochondrial swelling, depolarization, oxidative phosphorylation uncoupling and oxidative damage [52, 53].”
Sleep disturbance and kynurenine metabolism in depression
Cho, H. J., Savitz, J. B., Dantzer, R., Teague, T. K., Drevets, W. C., & Irwin, M. R. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.05.016 · Cited by 81
“Depression is increasingly conceptualized as a neuropathological condition characterized by regional abnormalities such as hippocampal volume reduction and glial cell loss [56].”
BackgroundSelf-citationDoes Serotonin Play a Role in Epilepsy?
Theodore, W. H. (2003) · Epiliepsy currents/Epilepsy currents · doi:10.1046/j.1535-7597.2003.03508.x · Cited by 80
“reuptake blockers are an important therapeutic modality (62).”
BackgroundPhysical Activity and Common Mental Disorder: Results from the Caerphilly Study
Wiles, N. J., Haase, A. M., Gallacher, J., Lawlor, D. A., & Lewis, G. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk070 · Cited by 76
“Substances such as brain-derived neurotrophic factor promote cell survival, and indirect regulation of such substances may explain some of the effectiveness of antidepressants (30).”
Gastrodiae Rhizoma (天麻 tiān má): a review of biological activity and antidepressant mechanisms
Chen, P., & Sheen, L. (2011) · Journal of Traditional and Complementary Medicine · doi:10.1016/s2225-4110(16)30054-2 · Cited by 80
“Previous studies indicated that the 3 key neurotransmitters, serotonin (5-HT), dopamine (DA), and norepinephrine (NE), are significantly lower in depressed patients’ brains (Manji et al., 2001).”
BackgroundChiou, S., Ku, H., Tsai, T., Lin, H., Chen, L., Chien, C., Ho, L. L. ‐., Lee, C., & Chang, Y. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706766 · Cited by 74
“Preliminary postmortem brain studies suggest the possible involvement of Bcl-2 in mood disorders, and the upregulation of Bcl-2 will exert trophic effects, and enhance cellular resilience, in the treatment of mood disorders (Manji et al., 2001; Bachmann et al., 2005).”
BackgroundLaw, A. J., Pei, Q., Walker, M., Gordon-Andrews, H., Weickert, C. S., Feldon, J., Pryce, C. R., & Harrison, P. J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.106 · Cited by 74
“…in the hypothalamopituitary-adrenal (HPA) axis (Sapolsky, 2000; Gunnar and Quevedo, 2007), the serotonin (5-HT) system (Gartside et al, 2003; Ichise et al, 2006), neurotrophins (Duman et al, 1997), and synaptic plasticity (Manji et al, 2001; Nestler et al, 2002; Pittenger and Duman, 2008).”
BackgroundBolaños, C. A., Wiley, M. D., Maffeo, M. L., Powers, K. D., Kinka, D. W., Grausam, K. B., & Henderson, R. P. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.024 · Cited by 81
Assessment of Depression in a Rodent Model of Spinal Cord Injury
Luedtke, K., Bouchard, S. M., Woller, S. A., Funk, M. K., Aceves, M., & Hook, M. A. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2013.3204 · Cited by 85
Gobbi, G., & Blier, P. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.032 · Cited by 77
Åberg, E., Losada, A. F., Sjöholm, L. K., Forsell, Y., & Lavebratt, C. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.009 · Cited by 83
“neurotransmitter systems, neurotrophic factors or plasticity impairments in neuronal networks (Castren, 2005; Coppen, 1967; Duman et al., 1997; Manji et al., 2001; Nestler et al., 2002; Schildkraut, 1965).”
BackgroundAbumaria, N., Ryguła, R., Hiemke, C., Fuchs, E., Havemann‐Reinecke, U., Rüther, E., & Flügge, G. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.08.009 · Cited by 86
“, 1997, 1999; Nestler, 1998) and/or reversing the structural changes in neurons as indicated by investigations in depressed humans (Manji et al., 2001; Manji and Duman, 2001).”
BackgroundDlaboga, D., HajjHussein, H., & O’Donnell, J. M. (2006) · Brain Research · doi:10.1016/j.brainres.2006.04.032 · Cited by 72
“These brain regions have been shown to be involved in the actions of antidepressant drugs ( Manji et al., 2001 ), suggesting that PDE4B and PDE4D may play different roles in mediation of antidepressant effects in the two species.”
BackgroundRincón‐Cortés, M., & Grace, A. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112367 · Cited by 80
“, 2016; Martin-Soelch, 2009), and human functional imaging and postmortem tissue studies have identified abnormalities in several brain regions, including nuclei within the brain’s reward pathway (Drevets, 2001; Manji et al., 2001; Price and Drevets, 2012; Whitton et al., 2015), which have been recapitulated in rodent…”
BackgroundFlaster, M. S., Sharma, A., & Rao, M. S. (2013) · Topics in Stroke Rehabilitation · doi:10.1310/tsr2002-139 · Cited by 85
Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
Quiroz, J. A., Singh, J. B., Gould, T. D., Denicoff, K. D., Zarate, C. A., & Manji, H. K. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001521 · Cited by 75
Self-citationClosed-Loop Implantable Therapeutic Neuromodulation Systems Based on Neurochemical Monitoring
Mirza, K. B., Golden, C. T., Nikolic, K., & Toumazou, C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00808 · Cited by 69
“This would indicate, that it is in fact, the downstream effects of increased serotonin that produce the therapeutic effect (Manji et al., 2001).”
BackgroundZou, Y., Zhang, Y., Tu, M., Ye, Y., Li, M., Ran, R., & Zou, Z. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110954 · Cited by 79
Anisman, H., Merali, Z., & Stead, J. D. H. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.001 · Cited by 77
Brain connectivity in psychiatric imaging genetics
Tost, H., Bilek, E., & Meyer‐Lindenberg, A. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.007 · Cited by 77
“A particularly useful example for the application is the pathophysiology of depression, a complex heritable condition affecting integrated pathways linking cortical, subcortical and limbic sites and their molecular mediators (Manji et al., 2001; Mayberg, 1997).”
BackgroundChanges in CREB-phosphorylation during recovery from major depression
Koch, J. M., Kell, S., Hinze‐Selch, D., & Aldenhoff, J. B. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00056-0 · Cited by 79
Fuchs, E., Cz??h, B., & Fl??gge, G. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200409000-00003 · Cited by 68
The Role of Glial Adenosine Receptors in Neural Resilience and the Neurobiology of Mood Disorders
van Calker, D., & Biber, K. P. H. (2005) · Neurochemical Research · doi:10.1007/s11064-005-8792-1 · Cited by 85
“While the issue of neural resilience has long been debated in the field of neurological disorders such as stroke or neurodegenerative illnesses, it has only recently received widespread attention as of potential pivotal importance in the neurobiological underpinnings of mood disorders and their treatment (24,25).”
The pharmacological management of depression
Kupfer, D. J. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/dkupfer · Cited by 69
“Most recently, attention has moved from intrasynaptic changes in neurotransmitter levels to changes in intracellular signaling pathways.(9) In an important review, Manji and colleagues(9) raise the possibility that depression may be associated with impairments in signaling pathways that are considered important for th…”
BackgroundEstrogen fluctuations during the menopausal transition are a risk factor for depressive disorders
Turek, J., & Gąsior, Ł. (2023) · Pharmacological Reports · doi:10.1007/s43440-022-00444-2 · Cited by 80
“These morphological and functional changes in nerve cells are associated with the activation of the HPA axis, the concomitant release of excessive glucocorticoids, and damage of glutamate, serotonin, and dopamine neurons [8].”
BackgroundDeterminants of suicidal ideation in patients with breast cancer
Kim, J., Jang, J., Stewart, R., Kim, S., Kim, S., Kang, H., Shin, I., Park, M., Yoon, J., & Yoon, J. (2013) · Psycho-Oncology · doi:10.1002/pon.3367 · Cited by 68
“In addition, chemotherapy (received by 70% participants) may also have an effect on BDNF expression according to BDNF polymorphism [47].”
BackgroundDobolyi, A., Palkovits, M., & Usdin, T. B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.10.017 · Cited by 69
Galanin Receptor Antagonists: A Potential Novel Pharmacological Treatment for Mood Disorders
Ögren, S. O., Kuteeva, E., kfelt, T. H., & Kehr, J. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00003 · Cited by 78
Stress, norepinephrine and depression
Leonard, B. E. (2002) · Acta Neuropsychiatrica · doi:10.1034/j.1601-5215.2002.140403.x · Cited by 68
Lee, M. T., Peng, W.-H., Kan, H.-W., Wu, C.-C., Wang, D.-W., & Ho, Y.-C. (2022) · Biomedicines · doi:10.3390/biomedicines10051005 · Cited by 65
“Clinically, most antidepressants target this system as a therapeutic goal, including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin, and norepinephrine reuptake inhibitors (SNRIs), to restore the levels of these monoamines [8].”
BackgroundHaj‐Mirzaian, A., Amiri, S., Kordjazy, N., Rahimi-Balaei, M., Haj‐Mirzaian, A., Marzban, H., Aminzadeh, A., Dehpour, A. R., & Mehr, S. E. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.01.006 · Cited by 71
Mood stabilizer psychopharmacology
Gould, T. D., Chen, G., & Manji, H. K. (2002) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(02)00044-0 · Cited by 72
Self-citationNeurobiology of bipolar disorder
Newberg, A. R., Catapano, L. A., Zarate, C. A., & Manji, H. K. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.1.93 · Cited by 75
Self-citationHayley, S. P., Du, L., Litteljohn, D., Palkovits, M., Faludi, G., Merali, Z., Poulter, M. O., & Anisman, H. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.05.052 · Cited by 78
Zhang, L.-L., Wang, J., Liu, Y., Lu, X., Kuang, Y., Wan, Y.-H., Chen, Y., Yan, H., Fei, J., & Wang, Z.-G. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.069 · Cited by 72
“…brain that regulate emotion, and the well-recognized fact that alteration in the signal transduction through GPCR pathways (Pierce et al., 2002) have been reported in the etiopathology of mood disorders (Manji and Lenox, 2000; Manji et al., 2001; Stockmeier, 2003; González-Maeso and Meana, 2006).”
BackgroundCanali, P., Sferrazza Papa, G., Casali, A. G., Schiena, G., Fecchio, M., Pigorini, A., Smeraldi, E., Colombo, C., & Benedetti, F. (2014) · Bipolar Disorders · doi:10.1111/bdi.12249 · Cited by 65
“Neuroimaging and postmortem studies revealed cellular and morphological changes in depression, associated with reduced grey matter volumes and abnormal decreases in neuron size and glial density (3, 4).”
BackgroundMackay, G. M., Forrest, C. M., Christofides, J., Bridel, M. A., Mitchell, S., Cowlard, R., Stone, T. W., & Darlington, L. G. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2008.05077.x · Cited by 66
“The earliest hypotheses, based on a simplistic concept of the need to achieve critical brain concentrations of monoamines, such as noradrenaline and 5-hydroxytryptamine (5-HT), to maintain synaptic transmission, have evolved into more sophisticated views based on changes in receptor function.(1) Some of the receptor c…”
BackgroundHetzenauer, A., Sinnegger-Brauns, M. J., Striessnig, J., & Singewald, N. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.01.059 · Cited by 65
Serotonergic and BDNF genes and risk of depression after stroke
Kim, J., Stewart, R. J., Bae, K., Kim, S., Kang, H., Shin, I., Kim, J., Park, M., Kim, M.-K., Park, S., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.09.029 · Cited by 75
Morphological Brain Changes in Depression: Can Antidepressants Reverse Them?
Miguel-Hidalgo, J. J., & Rajkowska, G. (2002) · CNS Drugs · doi:10.2165/00023210-200216060-00001 · Cited by 64
“[8,9] Some authors have even proposed that mechanisms that determine the degree of resiliency and structural sturdiness of neurons confronted with functional alterations or aggressions are important in mediating the positive effects of antidepressants.”
BackgroundBDNF genotype potentially modifying the association between incident stroke and depression
Kim, J.-M., Stewart, R., Kim, S.-W., Yang, S.-J., Shin, I.-S., Kim, Y.-H., & Yoon, J.-S. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.021 · Cited by 64
“…Robert Stewart b,∗, Sung-Wan Kim a, Su-Jin Yang a, Il-Seon Shin a, Young-Hoon Kim c, Jin-Sang Yoon a,∗∗ a Department of Psychiatry and Depression Clinical Research Center, Chonnam National University Medical School, Kwangju, Republic of Korea b King’s College London (Institute of Psychiatry),…”
BackgroundNeural Mechanisms of Exercise: Anti-Depression, Neurogenesis, and Serotonin Signaling
Yuan, T.-F., Paes, F., Arias-Carrión, O., Ferreira Rocha, N., de Sá Filho, A., & Machado, S. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666151111124402 · Cited by 65
“Patients with depression often display some form of HPA axis activation, and the subtypes of depression most frequently associated with HPA activation are those most likely to be associated with hippocampal volume reductions [50].”
BackgroundNitric oxide signalling and antidepressant action revisited
Joca, S. R. L., Sartim, A. G., Roncalho, A. L., Diniz, C. F. A., & Wegener, G. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-02987-4 · Cited by 63
Intracellular signaling pathways pave roads to recovery for mood disorders
Tanis, K. Q., & Duman, R. S. (2007) · Annals of Medicine · doi:10.1080/07853890701483270 · Cited by 69
Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders
Hesse, S., Barthel, H., SCHWARZ, J., Sabri, O., & Müller, U. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.08.004 · Cited by 66
Yamauchi, J., Miyamoto, Y., Murabe, M., Fujiwara, Y., Sanbe, A., Fujita, Y., Murase, S., & Tanoue, A. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.02.019 · Cited by 65
Garza, R. D. L., & Asnis, G. M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02757-4 · Cited by 67
Millard, S. J., Weston-Green, K., & Newell, K. A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109908 · Cited by 62
The involvement of ERK/CREB/Bcl-2 in depression-like behavior in prenatally stressed offspring rats
Guan, L., Jia, N., Zhao, X., Zhang, X., Tang, G., Yang, L., Sun, H., Wang, D., Su, Q., Song, Q., et al. (2013) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.08.003 · Cited by 65
Seo, M. K., Lee, C. H., Cho, H. Y., Lee, J. G., Lee, B. J., Kim, J. E., Seol, W., Kim, Y. H., & Park, S. W. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.019 · Cited by 68
Disrupting Disordered Neurocircuitry: Treating Refractory Psychiatric Illness With Neuromodulation
Tye, S. J., Frye, M. A., & Lee, K. H. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.6.522 · Cited by 72
Brain, networks, depression, and more
Leistedt, S., & Linkowski, P. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.10.011 · Cited by 69
“Furthermore, imaging and genetic studies are beginning to elucidate the neural structures involved in various mental health disorders and circuits that may be important targets for successful medications (Manji et al., 2001; Castr en, 2005).”
Background
Metadata
- Authors
- Manji, H. K., Drevets, W. C., & Charney, D. S.
- Affiliations
- National Institutes of Health (US)
- National Institute of Mental Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Medicine
- Published
- 2001-05
- Volume
- 7
- Issue
- 5
- Pages
- 541-547
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1509868652
- Cited by
- 1,182
- References
- 66
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 20 · 2023: 21 · 2022: 33 · 2021: 55 · 2020: 29 · 2019: 29 · 2018: 28 · 2017: 30 · 2016: 36 · 2015: 51 · 2014: 50 · 2013: 60 · 2012: 60
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- major depressive disorder, neurobiology of depression, neuroplasticity, cell survival, signaling pathways
- MeSH terms
- Antidepressive Agents, Cell Survival, Depressive Disorder, Glucocorticoids, Neuronal Plasticity, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.